Validation of Donor Oocytes Semi-automated Vitrification
NCT ID: NCT06238570
Last Updated: 2025-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
50 participants
INTERVENTIONAL
2024-01-23
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
However, the manual vitrification techniques used until now involve a learning curve and a potential variability of the completion time depending on the operator and the number of oocytes to be vitrified.
Oocyte vitrification is a key step to optimize the chances of pregnancy in ART after using these oocytes. However, manual vitrification requires a learning curve, is technician-dependent and requires significant technical time.
A semi-automatic vitrification device (GAVI®, Merck), which recently appeared on the market, has demonstrated its effectiveness in terms of speed of production and reproducibility of vitrification of embryos obtained in ART. To our knowledge, no study has analyzed the effectiveness of semi-automatic vitrification (GAVI®, Merck) on survival and oocyte quality after warming. It would therefore be interesting to evaluate the effectiveness of this automaton on oocyte vitrification in the context of oocyte donation and to determine the impact of semi-automatic vitrification on oocytes compared to manual vitrification.
The main objective of this study is to demonstrate the non-inferiority of vitrification semi-automated device (Gavi) of oocytes with regard to the oocyte survival rate, compared to the manual technique used in ART.
The investigator will compare the effectiveness of semi-automated vitrification device with the manual technique, in terms of ART results by comparing the fertilization rates, the number and quality of embryos obtained as well as the implantation rates in oocyte recipient patients. This study will then allow clinical application of the most efficient protocol for oocyte vitrification in the context of oocyte donation. A cost/effectiveness study will be carried out.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Interest of Automated Oocyte Freezing
NCT03570073
Methods for Fertility Preservation: Impact of Vitrification on in Vitro Matured Oocytes
NCT03680937
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
NCT03287479
Automation of Oocyte and Embryo Vitrification
NCT07197983
Effect of Vitrification and Warming Media on Pregnancy Rates in the Context of Oocyte Donation
NCT07288866
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The oocyte survival rate will be evaluated by the service technician or biologist. This survival rate corresponds to the ratio between the number of oocytes intact 2 hours after warming and able to be microinjected with a spermatozoon (ICSI), and the number of oocytes heated, after vitrification. We will compare the oocyte survival rate after vitrification and semi-automatic warming vs. after manual vitrification.
The investigator will compare the effectiveness of ART with oocyte donation during semi-automatic vitrification of oocytes compared to the manual technique, with regard to:
* Oocyte functional quality after warming evaluated by the fertilization rate of oocytes after ICSI
* Early development of embryos:
* the number of embryos cleaved on the 2nd day of culture from vitrified oocytes, the blastulation rate defined by the ratio between the number of blastocysts obtained (Gardner classification on the 5th day of culture) and the total number of cleaved embryos.
These parameters will be assessed daily during the embryo reading by a technician or a biologist from the ART department.
We will also compare the effectiveness of ART with oocyte donation during the semi-automatic vitrification of oocytes compared to the manual technique, with regard to:
* The implantation rate of embryos from vitrified oocytes, defined by the ratio between the number of embryo sacs observed (6th week of amenorrhea) and the number of embryos transferred
* The rate of miscarriages in oocyte recipients. These parameters will be evaluated by a biologist from the ART department after the results of the beta hCG of the patients and the performance of the ultrasound at the 6th week of amenorrhea by the gynecologists of the ART department.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Manual vitrification (using Vitrolife system)
The vitrification of the oocytes will be carried out by an authorized technician according to the manual protocol validated and used routinely.
Vitrolife system
The oocytes vitrification will be carried out by an authorized technician according to the manual protocol validated and used routinely.
Semi-automatic vitrification of oocytes using the GAVI® automaton (Merck)
The vitrification of the oocytes will be carried out using the GAVI® automaton
Gavi, Merck® (automated vitrification instrument)
This instrument recently appeared on the market and demonstrated a high effectiveness in terms of processing time and reproducibility for embryo vitrification. To date, no study has analyzed the efficiency of this automated vitrification instrument on oocyte vitrification.
The oocytes will be stored in closed cassettes in liquid nitrogen
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gavi, Merck® (automated vitrification instrument)
This instrument recently appeared on the market and demonstrated a high effectiveness in terms of processing time and reproducibility for embryo vitrification. To date, no study has analyzed the efficiency of this automated vitrification instrument on oocyte vitrification.
The oocytes will be stored in closed cassettes in liquid nitrogen
Vitrolife system
The oocytes vitrification will be carried out by an authorized technician according to the manual protocol validated and used routinely.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Oocyte puncture for donation
* Good quality ovarian reserve (Antral follicle count evaluated by ultrasound: CFA ≥ 7)
* Negative serology status (HIV, hepatitis B and C, syphilis, CMV and HTLV)
* Absence of symptoms or COVID contact
* Absence of genetic contraindication to egg donation
* Woman able to give informed consent to participate in research
* Woman affiliated to a social security scheme
Exclusion Criteria
* Pregnant and lactating woman
* Person under guardianship, curatorship, deprivation of liberty, protection of justice
18 Years
38 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Clermont-Ferrand
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AOI 2020 CHAPUT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.